EE62 Cost-Effectiveness of Neoadjuvant Pembrolizumab Plus Chemotherapy Followed By Adjuvant Pembrolizumab for High-Risk Early-Stage Triple-Negative Breast Cancer (ETNBC) in France

Saved in:

Bibliographic Details
Published in	Value in health Vol. 26; no. 12; p. S61
Main Authors	Cagnan, L., Haiderali, A., Bensimon, L., Tehard, B., Carita, M., Khandelwal, A., Gandhi, J., Huang, M.
Format	Journal Article
Language	English
Published	01.12.2023
Online Access	Get full text

Loading…

More Information
ISSN:	1098-3015
DOI:	10.1016/j.jval.2023.09.334